

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number 10/715,417

Filing Date November 19, 2003

First Named Inventor Eivind Per Thor STRATEN
et al.

Art Unit 1644

Examiner Name Marianne DIBRINO, Ph.D.

Attorney Docket Number 60820.000004

U.S. PATENT DOCUMENTS

*Examiner Initials	Case No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1.	US 2004/0210035		10-21-2004	Straten et al.	
2.	US 2007/0148184		06-28-2007	Straten et al.	
3.	US 6,037,135		03-14-2000	Kubo et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Case No.	FOREIGN PATENT DOCUMENT Country Code Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
4.	WO 03/102023		12-11-2003	Weinschenk et al.		<input type="checkbox"/>	<input type="checkbox"/>
5.	WO 04/067023		08-12-2004	Straten et al.		<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Case No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
6.	AMBROSINI et al., "Induction of Apoptosis and Inhibition of Cell Proliferation by Survivin Gene Targeting," The Journal of Biological Chemistry, Vol. 273, No. 18, Issue of May 1, pp. 11177-11182 (1998)		<input type="checkbox"/>	<input type="checkbox"/>
7.	BLOK et al., A Bispecific Monoclonal Antibody Directed Against Both Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and the Tumor Cell Lysis by Complement," The Journal of Immunology, Vol. 160, pp. 3437-3443 (1998)		<input type="checkbox"/>	<input type="checkbox"/>
8.	FORTUGNO et al., "Survivin Exists in Immunochemically Distinct Subcellular Pools and is Involved in Spindle Microtubule Function," Journal of Cell Science, Vol. 115, pp. 575-585, (2002)		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN <i>et al.</i>
Art Unit	1644
Examiner Name	Marianne DIBRINO, Ph.D.

Attorney Docket Number 60820.000004

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Ref. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	9.	GRUBE et al., "CD8 + T cells Reactive to Survivin Antigen in Patients with multiple Myeloma," Clinical Cancer Research, Vol. 13, No. 3, pp.1053-1060, February 1, 2007	<input type="checkbox"/>	<input type="checkbox"/>
	10.	HIROHASHI et al., "An HLA-24-Restricted Cytotoxic T Lymphocyte Epitope of a Tumor-Associated Protein, Survivin," Clinical Cancer Research, Vol. 8, pp. 1731-1739 (2002)	<input type="checkbox"/>	<input type="checkbox"/>
	11.	NIJMAN et al., Identification of peptide Sequences that Potentially Trigger HLA-A2.1-Restricted Cytotoxic T Lymphocytes," European Journal of Immunology, Vol. 23, pp. 1215-1219 (1993)	<input type="checkbox"/>	<input type="checkbox"/>
	12.	SCHMIDT et al., "Survivin is a Shared Tumor-Associated Antigen Expressed in a Broad Variety of Malignancies and Recognized by Specific Cytotoxic T Cells," Blood, Vol. 102, No. 2, pp. 571-576 (2003) XP-002283858	<input type="checkbox"/>	<input type="checkbox"/>
	13.	SCHMIDT et al., "Survivin is a Shared Tumor-Associated Antigen Expressed in a Broad Variety of Malignancies and Recognized by Specific Cytotoxic T Cells," Blood, Vol. 100, No. 11, Abstract No. 3675, November 16, 2002 XP-002283859	<input type="checkbox"/>	<input type="checkbox"/>
	14.	SORENSEN et al., "A Survivin Specific T-Cell Clone from a Breast Cancer Patient Displays Universal Tumor Cell Lysis," Cancer Biology & Therapy, Vol. 7, No. 12, pp. 1885-1887, December 2008	<input type="checkbox"/>	<input type="checkbox"/>
	15.	TITZER et al., "Vaccination of Multiple Myeloma Patients with Idiotype-Pulsed Dendritic Cells: Immunological and Clinical Aspects," British Journal of Haematology, Vol. 108, pp. 805-816 (2000)	<input type="checkbox"/>	<input type="checkbox"/>
	16.	International Search Report for International Application No. PCT/DK2004/000062, mailed September 1, 2004	<input type="checkbox"/>	<input type="checkbox"/>
	17.	International Preliminary Report on Patentability in International Application No. PCT/DK2004/000062, completed February 24, 2005	<input type="checkbox"/>	<input type="checkbox"/>
	18.	European Search Report for European Application No. 04 706 615, completed July 18, 2006	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.